Back to results
US 2019/0194329 A1Published application
Anti-4-1bb antibodies and their uses
AssigneeAbbVie Biotherapeutics Inc.
InventorsYoshiko AKAMATSU, Jieyi WANG
Life of this patent
Estimating the term…
Abstract
The present disclosure provides novel anti-4-1BB antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
Claims24
An anti-4-1BB antibody or binding fragment thereof comprising (i) a VH chain comprising three CDRs;
- and (ii) a VL chain comprising three CDRs, wherein:
- VH CDR#1 is
- (SEQ ID NO:
- 16)
- GYTFTSYYIY
- VH CDR#2 is
- (SEQ ID NO:
- 26)
- NIWPGNGGTFYGEKFMG
- VH CDR#3 is
- (SEQ ID NO:
- 36)
- RPDYSGDDYFDY
- VL CDR#1 is
- (SEQ ID NO:
- 56)
- KLNSGNIGSYYVH
- VL CDR#2 is
- (SEQ ID NO:
- 66)
- RDDKRPD
- VL CDR#3 is
- (SEQ ID NO:
- 76)
- HSYDSTITPV,
- or
- VH CDR#1 is
- (SEQ ID NO:
- 17)
- DYTFNDYWVS;
- VH CDR#2 is
- (SEQ ID NO:
- 27)
- EIYPNSGATNFNGKFRG;
- VH CDR#3 is
- (SEQ ID NO:
- 37)
- EYTRDWFAY;
- VL CDR#1 is
- (SEQ ID NO:
- 57)
- RSSQSLLDSDGNTYLY;
- VL CDR#2 is
- (SEQ ID NO:
- 67)
- LVSNLGS;
- VL CDR#3 is
- (SEQ ID NO:
- 77)
- MQPTHAPYT.
47 more elements
(canceled)
-12. (canceled)
-17. (canceled)
-20. (canceled)
(canceled)
Dependencies are inferred from the claim text.